Renal cell carcinoma (RCC) is the most common type of kidney or renal cancer, according to the American Cancer Society, with around 80-90% of the cancer cases reported being diagnosed as renal cell carcinoma. Transitional cell carcinoma (TCC) is another type of kidney cancer present among a few individuals (5% – 10% of the kidney cancer patients in the U.S.).
At times, surgical treatment alone is not sufficient for treating RCC; if a person has developed metastatic cancer, he/she ... Read more
Renal cell carcinoma (RCC) is the most common type of kidney or renal cancer, according to the American Cancer Society, with around 80-90% of the cancer cases reported being diagnosed as renal cell carcinoma. Transitional cell carcinoma (TCC) is another type of kidney cancer present among a few individuals (5% – 10% of the kidney cancer patients in the U.S.). At times, surgical treatment alone is not sufficient for treating RCC; if a person has developed metastatic cancer, he/she could be ... Read more
A report from TheBusinessResearchCompany shows that the "Global Kidney Cancer Drugs Market 2019" is expected to grow to $3.95 billion at a CAGR of 4.6% through 2022.
The Business Research Company’s Kidney Cancer Drugs Global Market Report 2019 covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends ... Read more
TheBusinessResearchCompany published its Kidney Cancer Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global kidney cancer drugs market. The report covers the kidney cancer drugs market’s segments- renal cell carcinoma (RCC), transitional cell carcinoma (TCC) or urothelial cell carcinoma (UCC), Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin ( ... Read more
The global Kidney Cancer Drugs Market Size is estimated to be valued at US$ 6.2 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Kidney cancer drugs are used for the treatment of one of the most common types of cancer, kidney cancer. These drugs function by slowing or stopping the growth of cancer cells or killing the cancer cells. Kidney cancer drugs include angiogenesis inhibitors, mTOR inhibitors, and vaccines. Angiogenesis inhibitors work by preventing the growth of new blood vessels that tumors need to grow. mTOR inhibitors slow tumor cell growth by blocking a specific protein called mTOR that helps tumor cells ... Read more
